KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $56.6 million.

  • Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 254.39% to $56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.6 million, marking a year-over-year increase of 254.39%. This contributed to the annual value of $55.1 million for FY2024, which is 103.38% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $56.6 million for Q3 2025, which was up 254.39% from $56.0 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $56.6 million during Q3 2025, and registered a low of $52.9 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $54.4 million, with a median of $54.5 million in 2023.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) surged by 74.75% in 2021, and later surged by 254.39% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $53.1 million in 2021, then grew by 1.07% to $53.7 million in 2022, then grew by 1.62% to $54.5 million in 2023, then grew by 1.03% to $55.1 million in 2024, then increased by 2.64% to $56.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $56.6 million for Q3 2025, versus $56.0 million for Q2 2025 and $55.9 million for Q1 2025.